Klonoff DC, et al. - In participants with type 1 diabetes (T1D), researchers assessed the effectiveness and safety of fast-acting insulin aspart (faster aspart) vs insulin aspart (IAsp) used in continuous subcutaneous insulin infusion (CSII). Faster aspart was non-inferior to IAsp in terms of the change in glycated haemoglobin from the baseline. No statistically significant difference was found in the overall rate of severe or blood glucose-confirmed hypoglycaemia. According to this double-blind, treat-to-target, randomized, 16-week trial, faster aspart gives an effective and safe option for CSII treatment in T1D.